These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8139136)

  • 1. Pravastatin administration to hyperlipidemia in patients with nephrotic syndrome.
    Shibasaki T; Nakano H; Matsuda H; Ohno I; Matsumoto H; Misawa T; Ishimoto F; Sakai O
    Nihon Jinzo Gakkai Shi; 1993 Nov; 35(11):1243-8. PubMed ID: 8139136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.
    Tokoo M; Oguchi H; Terashima M; Tokunaga S; Miyasaka M; Hora K; Higuchi M; Yoshie T; Furuta S
    Nihon Jinzo Gakkai Shi; 1992 Apr; 34(4):397-403. PubMed ID: 1635284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis?
    Muso E; Yashiro M; Matsushima M; Yoshida H; Sawanishi K; Sasayama S
    Nephrol Dial Transplant; 1994; 9(3):257-64. PubMed ID: 8052431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment].
    Okada T; Takahashi H; Ogura M; Nakao T; Shimizu T
    Nihon Jinzo Gakkai Shi; 1996 Jan; 38(1):46-51. PubMed ID: 8855137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus.
    Tawata M; Miwa I; Tsuchiya K; Ozawa M; Shindo H; Wakasugi M; Onaya T
    Arzneimittelforschung; 1995 Jun; 45(6):704-8. PubMed ID: 7646575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
    Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG subclass composition of monomeric and polymeric IgG in the serum of patients with nephrotic syndrome.
    Aro M; Hardwicke J
    Clin Nephrol; 1984 Nov; 22(5):244-52. PubMed ID: 6518674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of nephrotic syndrome in patients with glomerulonephritis.
    Sonkodi S; Tichy B; Mágori A; Ormos J
    Acta Med Hung; 1986; 43(3):311-3. PubMed ID: 3588169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menopause and hyperlipidemia: pravastatin lowers lipid levels without decreasing endogenous estrogens.
    Honjo H; Tanaka K; Urabe M; Naitoh K; Ogino Y; Yamamoto T; Okada H
    Clin Ther; 1992; 14(5):699-707. PubMed ID: 1345259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incidental mesangial IgA deposition in minimal change nephrotic syndrome(MCNS)].
    Tsukada M; Honda K; Nitta K; Yumura W; Nihei H
    Nihon Jinzo Gakkai Shi; 2003 Oct; 45(7):681-8. PubMed ID: 14631763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of nephrotic syndrome associated with minimal renal amyloidosis--a four-year follow-up].
    Makibayashi K; Yanagita M; Kanatsu K
    Nihon Jinzo Gakkai Shi; 1997 Jul; 39(5):507-11. PubMed ID: 9283217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological diagnosis and outcome of paediatric nephrotic syndrome.
    Ejaz I; Khan HI; Javaid BK; Rasool G; Bhatti MT
    J Coll Physicians Surg Pak; 2004 Apr; 14(4):229-33. PubMed ID: 15228828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell subsets in glomerulonephritis.
    Lin CY; Yang YM; Fu YK
    Int J Pediatr Nephrol; 1986; 7(2):63-8. PubMed ID: 3487514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Am J Cardiol; 2010 Sep; 106(6):787-92. PubMed ID: 20816118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotic syndrome in African children: lack of evidence for 'tropical nephrotic syndrome'?
    Doe JY; Funk M; Mengel M; Doehring E; Ehrich JH
    Nephrol Dial Transplant; 2006 Mar; 21(3):672-6. PubMed ID: 16326742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
    Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
    Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pefloxacin as a first-line treatment for nephrotic syndrome in minimal glomerular lesions in the adult. Multicenter study of 32 patients].
    Pruna A; Barka A; Nochy D; Hauet T; Boulanger H; Landais P
    Nephrologie; 1997; 18(3):95-101. PubMed ID: 9297136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of lipid and fatty acid metabolism between minimal change nephrotic syndrome and membranous nephropathy.
    Fujita T; Nakamura N; Kumasaka R; Shimada M; Murakami R; Osawa H; Yamabe H; Okumura K
    In Vivo; 2006; 20(6B):891-3. PubMed ID: 17203785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome.
    Prasher PK; Varma PP; Baliga KV
    J Assoc Physicians India; 1999 Feb; 47(2):180-2. PubMed ID: 10999084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.